Brief: Aelis Farma Says IDMC Identifies No Safety Concern In Phase 2B Study Of AEF0217
16/07/2026 08:01
BRIEF-Aelis Farma Says IDMC Identifies No Safety Concern In Phase 2B Study Of AEF0217 July 16 (Reuters) - Aelis Farma SA AELIS.PA:
AELIS FARMA RECEIVES A POSITIVE RECOMMENDATION FROM THE INDEPENDENT DATA MONITORING COMMITTEE TO CONTINUE THE PHASE 2B STUDY OF AEF0217 IN PEOPLE WITH DOWN SYNDROME WITHOUT MODIFICATION
AELIS FARMA - IDMC IDENTIFIES NO SAFETY CONCERN IN PHASE 2B STUDY OF AEF0217
Source text: ID:nBwbFz7PGa
Further company coverage: AELIS.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aelis Farma SA
See all newsBrief: Aelis Farma Says IDMC Identifies No Safety Concern In Phase 2B Study Of AEF0217
Brief: Aelis Farma Availability Of 2025 Half-Year Financial Report
Brief: Euronext: Quarterly Review Of CAC Family
Brief: Aelis Farma Confirms Its 2025 Outlook
Brief: Aelis Farma Announces The Final Analysis Of Phase 2B Clinical Trial In Cannabis Use Disorder With AEF0117